Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. Announce Certification of a Class of Third Party Payors Who Purchased or Paid for Some or All of the Price of Stelara

Key Takeaways:

• A federal court has certified a class of involved third-party payors.
• Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. are leading the case.
• The case centers on costs associated with the medication Stelara.
• The announcement originated from Boston on December 8, 2025.
• Auburnpub reported the story, categorizing it under business and top news.

Certification Announcement

A class of third-party payors who purchased or paid for some or all of the price of Stelara has been officially certified. According to the December 8, 2025 announcement from Boston, this development marks a formal step in the legal proceedings concerning the medication’s cost.

Law Firms Involved

Key legal representation is provided by Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. The press release identifies these two firms as instrumental in attaining class certification, signaling a measure of progress in the broader dispute over Stelara expenses.

Relevance to Third Party Payors

This certified class primarily includes payors who have borne costs for Stelara. The certification may influence how parties tackle insurance-related duties and cost-sharing responsibilities linked to pharmaceutical products.

Context and Timing

Released under the auspices of a press release on December 8, 2025, the announcement underscores the critical timing of this certification. Reports from Auburnpub place the story in its “business” and “top” categories, reflecting its significance in the business and legal realms.

Legal Implications

While specific legal implications are not detailed in the public announcement, the certification signifies that a broader group of affected payors can move forward collectively in any upcoming phases. The outcome could potentially shape discussions around medication costs and reimbursement processes for healthcare services.

Looking Ahead

No additional information is available about the subsequent steps in this legal process, as only limited details were provided in the news feed. However, given the certification milestone, parties invested in pharmaceutical pricing and reimbursement will likely observe the next stages with keen interest.